Evaluation of penicillin G potassium troches in the treatment of minor recurrent aphthous ulceration in a Chinese cohort: a randomized, double-blinded, placebo and no-treatment–controlled, multicenter clinical trial

Zhou, Yu; Chen, Qiaming; Meng, Wenxia; Jiang, Lu; Wang, Zhi; Liu, Jie; Lin, Mei; Zhou, Hongmei; Chen, Xiaofang; Zhao, Man; Zeng, Xin

doi:10.1016/j.tripleo.2009.11.006

Cited by 23 publications

(21 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In major and minor RAS, topical tetracycline or minocycline mouthwashes as a local anti-bacterial can be expected to reduce the severity of the ulcerations and pain but not prevent recurrences [60,61]. Similar effectiveness in promoting healing and reducing pain has been reported with penicillin G mouthwashes [62].…”

Section: Topical Therapiesmentioning

confidence: 87%

Recurrent Aphthous Stomatitis: Towards Evidence-Based Treatment?

Challacombe

Alsahaf

Tappuni

2015

Curr Oral Health Rep

View full text Add to dashboard Cite

Recurrent aphthous stomatitis is one of the most common oral mucosal diseases seen by dental professionals, and yet its aetiology remains unclear, and its management based on less than robust evidence. The literature remains confused because of the lack of clarity in diagnosis and the lack of a standardised ulcer severity scoring system and agreed outcome measures. However, recent literature is encouraging in meeting these aims. There is agreement that recurrent aphthous stomatitis (RAS) is a localized mucosal disease not secondary to systemic disease and therefore distinguishable from over 40 other types of oral ulcers. Disease severity scores have been introduced and outcome measures have become more standardised. RAS appears to be an autoimmune disease directed at epitopes of heat shock proteins whilst most recent work on aetiology has focused on cytokines and genetics. Pro-inflammatory cytokines including TNF-a and IL-6 and IL-17 are raised in RAS and TNF inhibitors can inhibit episodes of ulceration. Many local antiinflammatory agents will help ulcers heal, and local steroids remain the treatment of choice. Some systemic drugs have evidence-based data indicating efficacy at preventing new ulcers including colchicine, prednisolone, thalidomide, pentoxyfilline and dapsone. The field would benefit from further trials combining local and systemic therapy using defined outcome measures.

show abstract

Section: Topical Therapiesmentioning

confidence: 87%

Recurrent Aphthous Stomatitis: Towards Evidence-Based Treatment?

Challacombe

Alsahaf

Tappuni

2015

Curr Oral Health Rep

View full text Add to dashboard Cite

show abstract

“…The underlying etiology is not clear, though a series of factors are known to predispose to the appearance of oral aphthae, including genetic factors, food allergens, local trauma, endocrine alterations (menstrual cycle), stress and anxiety, smoking cessation, certain chemical products and microbial agents (2-5,8,9). Immune alterations have been observed, beginning with an unknown antigenic stimulation of the keratinocytes, and resulting in the activation of T lymphocytes, cytokine secretion (including tumor necrosis factor-alpha (TNF-α), and leukocyte chemotaxis.…”

Section: Introductionmentioning

confidence: 99%

“…Each minor RAS episode usually involves the appearance of 1-5 ulcers measuring under 1 cm in diameter. These episodes are self-limiting and resolve within 4-14 days without leaving scars (3-5,7,9). …”

Section: Introductionmentioning

confidence: 99%

Treatment of recurrent aphthous stomatitis. A literature review

2014

View full text Add to dashboard Cite

Recurrent aphthous stomatitis (RAS) is the most common chronic disease of the oral cavity, affecting 5-25% of the population. The underlying etiology remains unclear, and no curative treatment is available. The present review examines the existing treatments for RAS with the purpose of answering a number of questions: How should these patients be treated in the dental clinic? What topical drugs are available and when should they be used? What systemic drugs are available and when should they be used? A literature search was made of the PubMed, Cochrane and Scopus databases, limited to articles published between 2008-2012, with scientific levels of evidence 1 and 2 (metaanalyses, systematic reviews, phase I and II randomized clinical trials, cohort studies and case-control studies), and conducted in humans. The results obtained indicate that the management of RAS should be based on identification and control of the possible predisposing factors, with the exclusion of possible underlying systemic causes, and the use of a detailed clinical history along with complementary procedures such as laboratory tests, where required. Only in the case of continuous outbreaks and symptoms should drug treatment be prescribed, with the initial application of local treatments in all cases. A broad range of topical medications are available, including antiseptics (chlorhexidine), antiinflammatory drugs (amlexanox), antibiotics (tetracyclines) and corticosteroids (triamcinolone acetonide). In patients with constant and aggressive outbreaks (major aphthae), pain is intense and topical treatment is unable to afford symptoms relief. Systemic therapy is indicated in such situations, in the form of corticosteroids (prednisone) or thalidomide, among other drugs. Key words:Recurrent aphthous stomatitis, treatment, clinical management.

show abstract

“…Dois ensaios clínicos presentes nesta revisão integrativa estudaram a utilização de antibióticos no manejo da EAR, o hiclato de doxiciclina 5 , em aplicação tópica única, e a penicilina G potássica 28 , em aplicação tópica quatro vezes ao dia. A doxiciclina mostrou-se eficaz na redução da dor causada pela úlcera, promovendo recuperação acelerada, e a penicilina G potássica também atuou no alívio da dor e auxiliou, ainda, na redução do tamanho da úlcera.…”

Section: Discussionunclassified

“…Regimes tópicos e sistêmicos de tetraciclinas têm sido utilizados no manejo da EAR, não somente devido às suas propriedades antimicrobianas, mas também devido a outras propriedades, tais como inibição da produção de prostaglandinas, supressão de leucócitos, inibição de colagenases e gelatinases 28 . Quanto à utilização de penicilinas, embora o mecanismo de ação na EAR permaneça indefinido, acredita-se que a eficácia esteja relacionada aos efeitos do antibiótico contra o Streptococcus spp 5 .…”

Section: Discussionunclassified

Tratamento da estomatite aftosa recorrente: uma revisão integrativa da literatura

Vieira

Carmo

Vieira

et al. 2016

Rev. da Fac. de Odontologia, UPF

View full text Add to dashboard Cite

IntroduçãoA estomatite aftosa recorrente (EAR) é uma condição comum caracterizada por úlceras múltiplas, pequenas, ovoides, com margem circunscrita, halo eritematoso e fundo amarelo ou cinza, com aparecimento típico primeiramente na infância ou adolescência 1 . A manifestação dessa alteração dá-se em surtos e com um curso crônico, com tempo limitado da lesão, na maior parte dos casos 2,3 . Do ponto de vista epidemiológico, a EAR é uma das mais comuns desordens orais, conhecida por afetar cerca de 20% da população em algum momento da vida 4 . Apesar de sua alta prevalência na população, sua etiopatogenia perdura como um enigma, pois, mesmo com muitas investigações, os estudos têm falhado em encontrar a sua exata etiologia

show abstract

Evaluation of penicillin G potassium troches in the treatment of minor recurrent aphthous ulceration in a Chinese cohort: a randomized, double-blinded, placebo and no-treatment–controlled, multicenter clinical trial

Cited by 23 publications

References 16 publications

Recurrent Aphthous Stomatitis: Towards Evidence-Based Treatment?

Recurrent Aphthous Stomatitis: Towards Evidence-Based Treatment?

Treatment of recurrent aphthous stomatitis. A literature review

Tratamento da estomatite aftosa recorrente: uma revisão integrativa da literatura

Contact Info

Product

Resources

About